Intratumoral PD1⁺CD38⁺Tim3⁺ CD8⁺ T Cells in Pre-BCG Tumor Tissues Are Associated with Poor Responsiveness to BCG Immunotherapy in Patients with Non-Muscle Invasive Bladder Cancer.

ABSTRACT: Intravesical immunotherapy with Bacillus Calmette-Guerin (BCG) is a standard of care therapy for non-muscle invasive bladder cancer (NMIBC), which accounts for about 75% of newly diagnosed urothelial cancer. However, given the frequent recurrence and progression, identification of a pre-treatment biomarker capable of predicting responsiveness to BCG in NMIBC is of utmost importance. Herein, using multiparametric flow cytometry, we characterized CD8⁺ T cells from peripheral blood and tumor tissues collected from 27 pre-BCG patients bearing NMIBC to obtain immune correlates of bladder cancer prognosis and responsiveness to BCG therapy. We observed that intratumoral CD8⁺ T cell subsets were highly heterogenous in terms of their differentiation state and exist at differen

SUBMITTER: Basak D 

PROVIDER: S-EPMC10416886 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature